Immunohistochemical studies and fluorodeoxyglucose uptake on positron emission tomography in pharyngeal cancer for predicting radiotherapy-based treatment outcomes

Y. C. Lin, R. Y. Chen, S. W. Chen, T. C. Hsieh, K. Y. Yen, J. A. Liang, S. N. Yang, Y. C. Wang, Y. H. Chen, Nan-Haw Chow, C. H. Kao

研究成果: Article

2 引文 (Scopus)

摘要

Objectives: This study correlated immunohistochemical studies with fluorodeoxyglucose (FDG) uptake on positron emission tomography–computed tomography (PET–CT) and identified prognostic factors for radiotherapy (RT)-based treatment outcomes in patients with squamous cell carcinoma of the oropharynx and hypopharynx. Methods: Genomic data from pre-treatment biopsy specimens (Glut1, CAIX, VEGF, HIF-1α, EGFR, Ki-67, Bcl-2, CLAUDIN-4, YAP-1, c-Met and p16) of 76 patients were analysed using tissue microarrays. FDG uptake was evaluated using the maximum standardised uptake value (SUVmax), metabolic tumour volume (MTV) and total lesion glycolysis (TLG). Results: The overexpression of Glut1 positively associated with increased values of the SUVmax, MTV and TLG, whereas VEGF and HIF-1α expression with the MTV and TLG, respectively. A VEGF immunoreactive score (IRS) >2 (P = 0.001, hazard ratio [HR] = 3.94) and an MTV defined by an SUV of 2.5 (MTV2.5) >14.5 mL (P = 0.004, HR = 3.31) were prognostic factors for low cause-specific survival, whereas a VEGF IRS >2 (P = 0.02, HR = 2.83) for low primary relapse-free survival. Conclusion: The overexpression of Glut1, VEGF and HIF-1α associated with increased FDG uptake. For patients with pharyngeal cancer requiring RT, the treatment outcome can be stratified by VEGF and MTV2.5.

原文English
頁(從 - 到)608-619
頁數12
期刊Clinical Otolaryngology
42
發行號3
DOIs
出版狀態Published - 2017 六月 1

指紋

Pharyngeal Neoplasms
Positron-Emission Tomography
Vascular Endothelial Growth Factor A
Radiotherapy
Tumor Burden
Glycolysis
Hypopharynx
Oropharynx
Survival
Squamous Cell Carcinoma
Biopsy
Recurrence

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

引用此文

Lin, Y. C. ; Chen, R. Y. ; Chen, S. W. ; Hsieh, T. C. ; Yen, K. Y. ; Liang, J. A. ; Yang, S. N. ; Wang, Y. C. ; Chen, Y. H. ; Chow, Nan-Haw ; Kao, C. H. / Immunohistochemical studies and fluorodeoxyglucose uptake on positron emission tomography in pharyngeal cancer for predicting radiotherapy-based treatment outcomes. 於: Clinical Otolaryngology. 2017 ; 卷 42, 編號 3. 頁 608-619.
@article{8f6a5563fba3412bb1b9c17690b1797b,
title = "Immunohistochemical studies and fluorodeoxyglucose uptake on positron emission tomography in pharyngeal cancer for predicting radiotherapy-based treatment outcomes",
abstract = "Objectives: This study correlated immunohistochemical studies with fluorodeoxyglucose (FDG) uptake on positron emission tomography–computed tomography (PET–CT) and identified prognostic factors for radiotherapy (RT)-based treatment outcomes in patients with squamous cell carcinoma of the oropharynx and hypopharynx. Methods: Genomic data from pre-treatment biopsy specimens (Glut1, CAIX, VEGF, HIF-1α, EGFR, Ki-67, Bcl-2, CLAUDIN-4, YAP-1, c-Met and p16) of 76 patients were analysed using tissue microarrays. FDG uptake was evaluated using the maximum standardised uptake value (SUVmax), metabolic tumour volume (MTV) and total lesion glycolysis (TLG). Results: The overexpression of Glut1 positively associated with increased values of the SUVmax, MTV and TLG, whereas VEGF and HIF-1α expression with the MTV and TLG, respectively. A VEGF immunoreactive score (IRS) >2 (P = 0.001, hazard ratio [HR] = 3.94) and an MTV defined by an SUV of 2.5 (MTV2.5) >14.5 mL (P = 0.004, HR = 3.31) were prognostic factors for low cause-specific survival, whereas a VEGF IRS >2 (P = 0.02, HR = 2.83) for low primary relapse-free survival. Conclusion: The overexpression of Glut1, VEGF and HIF-1α associated with increased FDG uptake. For patients with pharyngeal cancer requiring RT, the treatment outcome can be stratified by VEGF and MTV2.5.",
author = "Lin, {Y. C.} and Chen, {R. Y.} and Chen, {S. W.} and Hsieh, {T. C.} and Yen, {K. Y.} and Liang, {J. A.} and Yang, {S. N.} and Wang, {Y. C.} and Chen, {Y. H.} and Nan-Haw Chow and Kao, {C. H.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1111/coa.12783",
language = "English",
volume = "42",
pages = "608--619",
journal = "Clinical Otolaryngology",
issn = "1749-4478",
publisher = "Wiley-Blackwell",
number = "3",

}

Immunohistochemical studies and fluorodeoxyglucose uptake on positron emission tomography in pharyngeal cancer for predicting radiotherapy-based treatment outcomes. / Lin, Y. C.; Chen, R. Y.; Chen, S. W.; Hsieh, T. C.; Yen, K. Y.; Liang, J. A.; Yang, S. N.; Wang, Y. C.; Chen, Y. H.; Chow, Nan-Haw; Kao, C. H.

於: Clinical Otolaryngology, 卷 42, 編號 3, 01.06.2017, p. 608-619.

研究成果: Article

TY - JOUR

T1 - Immunohistochemical studies and fluorodeoxyglucose uptake on positron emission tomography in pharyngeal cancer for predicting radiotherapy-based treatment outcomes

AU - Lin, Y. C.

AU - Chen, R. Y.

AU - Chen, S. W.

AU - Hsieh, T. C.

AU - Yen, K. Y.

AU - Liang, J. A.

AU - Yang, S. N.

AU - Wang, Y. C.

AU - Chen, Y. H.

AU - Chow, Nan-Haw

AU - Kao, C. H.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Objectives: This study correlated immunohistochemical studies with fluorodeoxyglucose (FDG) uptake on positron emission tomography–computed tomography (PET–CT) and identified prognostic factors for radiotherapy (RT)-based treatment outcomes in patients with squamous cell carcinoma of the oropharynx and hypopharynx. Methods: Genomic data from pre-treatment biopsy specimens (Glut1, CAIX, VEGF, HIF-1α, EGFR, Ki-67, Bcl-2, CLAUDIN-4, YAP-1, c-Met and p16) of 76 patients were analysed using tissue microarrays. FDG uptake was evaluated using the maximum standardised uptake value (SUVmax), metabolic tumour volume (MTV) and total lesion glycolysis (TLG). Results: The overexpression of Glut1 positively associated with increased values of the SUVmax, MTV and TLG, whereas VEGF and HIF-1α expression with the MTV and TLG, respectively. A VEGF immunoreactive score (IRS) >2 (P = 0.001, hazard ratio [HR] = 3.94) and an MTV defined by an SUV of 2.5 (MTV2.5) >14.5 mL (P = 0.004, HR = 3.31) were prognostic factors for low cause-specific survival, whereas a VEGF IRS >2 (P = 0.02, HR = 2.83) for low primary relapse-free survival. Conclusion: The overexpression of Glut1, VEGF and HIF-1α associated with increased FDG uptake. For patients with pharyngeal cancer requiring RT, the treatment outcome can be stratified by VEGF and MTV2.5.

AB - Objectives: This study correlated immunohistochemical studies with fluorodeoxyglucose (FDG) uptake on positron emission tomography–computed tomography (PET–CT) and identified prognostic factors for radiotherapy (RT)-based treatment outcomes in patients with squamous cell carcinoma of the oropharynx and hypopharynx. Methods: Genomic data from pre-treatment biopsy specimens (Glut1, CAIX, VEGF, HIF-1α, EGFR, Ki-67, Bcl-2, CLAUDIN-4, YAP-1, c-Met and p16) of 76 patients were analysed using tissue microarrays. FDG uptake was evaluated using the maximum standardised uptake value (SUVmax), metabolic tumour volume (MTV) and total lesion glycolysis (TLG). Results: The overexpression of Glut1 positively associated with increased values of the SUVmax, MTV and TLG, whereas VEGF and HIF-1α expression with the MTV and TLG, respectively. A VEGF immunoreactive score (IRS) >2 (P = 0.001, hazard ratio [HR] = 3.94) and an MTV defined by an SUV of 2.5 (MTV2.5) >14.5 mL (P = 0.004, HR = 3.31) were prognostic factors for low cause-specific survival, whereas a VEGF IRS >2 (P = 0.02, HR = 2.83) for low primary relapse-free survival. Conclusion: The overexpression of Glut1, VEGF and HIF-1α associated with increased FDG uptake. For patients with pharyngeal cancer requiring RT, the treatment outcome can be stratified by VEGF and MTV2.5.

UR - http://www.scopus.com/inward/record.url?scp=84995679777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995679777&partnerID=8YFLogxK

U2 - 10.1111/coa.12783

DO - 10.1111/coa.12783

M3 - Article

C2 - 27762071

AN - SCOPUS:84995679777

VL - 42

SP - 608

EP - 619

JO - Clinical Otolaryngology

JF - Clinical Otolaryngology

SN - 1749-4478

IS - 3

ER -